Archive Adhoc- and Press releases 2012

ENGLISH DEUTSCH
12 December 2012
PR: WILEX Inc. signs distribution agreement with Immundiagnostik AG for D-A-CH region
04 December 2012
PR: WILEX AG announces restructuring
26 October 2012
Letter to the shareholders
16 October 2012
AH: WILEX AG announces results of Phase III ARISER study with RENCAREX® in clear cell renal cell carcinoma
PR: WILEX AG announces results of Phase III ARISER study with RENCAREX® in clear cell renal cell carcinoma 
11 October 2012
PR: WILEX publishes 9-months financial report 2012
05 October 2012
PR: WILEX AG and the FDA agree on the further development of REDECTANE®
24 August 2012
AH: WILEX AG successfully completes combined capital increase of cash and contribution in kind totalling EUR 23.9 million
PM: WILEX AG successfully completes combined capital increase of cash and contribution in kind totalling EUR 23.9 million
07 August 2012
PR: WILEX announces planned change to Executive Management Board
03 August 2012
AH: WILEX AG plans rights offering and combined capital increase of cash and contribution in kind
25 July 2012
PR: WILEX AG reports on Oncologic Drugs Advisory Committee (ODAC) meeting and positive vote on diagnostic imaging
12 July 2012
PR: WILEX announces results of successful first half year 2012
06 July 2012
AH: WILEX AG opts for further payment under the licence agreement with Prometheus
14 June 2012
AH: MESUPRON® met its primary objective of demonstrating efficacy in the proof of concept phase II breast cancer trial
PR: MESUPRON® met its primary objective of demonstrating efficacy in the proof of concept phase II breast cancer trial
25 May 2012
PR: WILEX reports on Annual General Meeting 2012
12 April 2012
PR: WILEX publishes financial report for the first quarter of 2012
11 April 2012
PR: WILEX starts first patient study with MEK inhibitor WX-554
28 February 2012
PR: WILEX reports on a successful financial year 2011
27 February 2012
PR: FDA approves protocol amendment needed to conduct the final analysis of the pivotal RENCAREX® Phase III trial
15 February 2012
PR: WILEX Inc. appoints Walter Carney as CSO for the further development of Oncogene Science diagnostics
06 February 2012
PR: WILEX receives funding from the German Federal Ministry of Education and Research for the development of WX-037 as part of the “m4 cluster initiative”
01 February 2012
AH: WILEX AG successfully completes rights issue
18 January 2012
PR: WILEX successfully completed Phase I study in Healthy Volunteers with the oral MEK inhibitor WX-554
09 January 2012
AH: WILEX AG resolves rights issue using authorised capital
Seite gelesen: 503 | Heute: 3